北京五和博澳药业

Beijing Wuheboao Pharmaceutical is a Chinese biopharmaceutical company focused on the research, development, and commercialization of innovative drugs for metabolic diseases and oncology. The company is best known for its flagship product, Sangguayin (Mulberry Twig Alkaloids), which is a first-in-class botanical drug approved in China for the treatment of type 2 diabetes. Wuheboao utilizes a proprietary natural medicine innovation platform to extract and purify active compounds from traditional Chinese medicinal sources. Its pipeline includes several candidates targeting metabolic pathways, such as SGLT2 and GLP-1, as well as anti-tumor agents. Headquartered in Beijing, the company maintains integrated R&D and GMP-certified manufacturing facilities to support its full-cycle drug development strategy.